Pharmaceutical

J&Js Rybrevant plus Lazcluze combination gets FDA approval in NSCLC

J&J said the drug combination is now the first and only multitargeted, chemotherapy-free combination regimen proven to be superior to Tagrisso.

Aug 21, 2024 - 04:00
J&Js Rybrevant plus Lazcluze combination gets FDA approval in NSCLC
J&J said the drug combination is now the first and only multitargeted, chemotherapy-free combination regimen proven to be superior to Tagrisso.
Read the original article

Tags:

Previous Article

Adcendo and Multitude ink ADC deal potentially worth $1bn

Next Article

ReAlta secures FDA orphan drug and fast track designations for GvHD therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: OB-GYNs could have solidified abortion as health care after Roe. They missed their chance

Opinion: OB-GYNs could have solidified abortion as heal...

Jun 24, 2023

STAT+: Amy Abernethy to step down as Verily’s chief medical officer in latest departure from company

STAT+: Amy Abernethy to step down as Verily’s chief med...

Dec 19, 2023

Bayer wins FDA breakthrough therapy designation for NSCLC candidate

Bayer wins FDA breakthrough therapy designation for NSC...

Feb 26, 2024